Novel and emerging drugs for acute myeloid leukemia: Pharmacology and therapeutic activity

Current Medicinal Chemistry

Volumn 18, Issue 5, 2011, Pages 638-666

  Robak, T ^a   Szmigielska Kaplon A ^a   Pluta, A ^a   Grzybowska Izydorczyk, O ^b   Wolska, A ^a   Czemerska, M ^a   Wierzbowska, A ^a  

^a Department of Hematology ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

AML; Farnesyl transferase inhibitors; Histone deacetylase inhibitors; Hypomethylating agents; Liposomal daunorubicin; Monoclonal antibodies; MTOR kinase inhibitors; Nucleoside analogs

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 5 AZA 2' DEOXYCYTIDINE; AXITINIB; AZACITIDINE; BEVACIZUMAB; CD135 ANTIGEN; CLOFARABINE; CLORAL; CPX 351; CS 6821; CYC 682; CYTARABINE; CYTIDINE; DASATINIB; DAUNORUBICIN; DEPSIPEPTIDE; ELACYTARABINE; ENTINOSTAT; ETOPOSIDE; EVEROLIMUS; GEMTUZUMAB OZOGAMICIN; GLIVEK; HISTONE DEACETYLASE INHIBITOR; IMATINIB; ISTODAX; LAROMUSTINE; LESTAURINIB; LESTAURTINIB; LINTUZUMAB; LONAFARNIB; MIDOSTAURIN; MOCETINOSTAT; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; PANOBINOSTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRIMIDINE NUCLEOSIDE DERIVATIVE; RAPAMYCIN; RIDAFOROLIMUS; SAPACITABINE; SEMAXANIB; SORAFENIB; SUNITINIB; TANDUTINIB; TEMSIROLIMUS; TIPIFARNIB; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VALSPODAR; VORINOSTAT; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER REGRESSION; COLONY FORMING CELL; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; GENE MUTATION; HUMAN; METHYLATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; TREATMENT RESPONSE;

ADENINE NUCLEOTIDES; ANIMALS; ARABINONUCLEOSIDES; AZACITIDINE; CYTARABINE; CYTOSINE; DAUNORUBICIN; DIOXOLANES; FARNESYLTRANSTRANSFERASE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDRAZINES; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SULFONAMIDES; TOR SERINE-THREONINE KINASES; VALPROIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 79951530814     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794480104     Document Type: Article

References (231)

1. Deschler, B.; Lubbert, M. Acute myeloid leukemia: epidemiology (Pubitemid 44665642)
2. Aquino, V. M.; Acute myelogenous leukemia. Curr. Probl. Pediatr. Adolesc. Health Care, 2002, 32(2), 50-58. (Pubitemid 41128010)
3. Atlanta GACS. Cancer Facts Figures. 2008.
4. Robak, T.; Wierzbowska, A. Current and emerging therapies for acute myeloid leukemia. Clin. Ther., 2009, 31, 2349-2370.
5. Blum, W.; Marcucci, G. New approaches in acute myeloid leukemia. Best Pract. Res. Clin. Haematol., 2008, 21(1), 29-41. (Pubitemid 351377512)
6. Stasi, R.; Evangelista, M. L.; Buccisano, F.; Venditti, A.; Amadori, S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat. Rev., 2008, 34(1), 49-60. (Pubitemid 351168609)
7. Stone, R. M. Targeted agents in AML: much more to do. Best Pract. Res. Clin. Haematol., 2007, 20(1), 39-48.
8. Forssen, A.; Ross, M. E. DaunoXome treatment of solid tumors: preclinical and clinical investigations. J. Liposome Res., 1994, 4, 481-512. (Pubitemid 24130557)
9. Pea, F.; Russo, D.; Michieli, M.; Baraldo, M.; Ermacora, A.; Damiani, D.; Baccarani, M.; Furlanut, M. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Cancer Chemother. Pharmacol., 2000, 46(4), 279-286.
10. Richardson, D. S.; Kelsey, S. M.; Johnson, S. A.; Tighe, M.; Cavenagh, J. D.; Newland, A. C. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest. New Drugs, 1997, 15(3), 247-253. (Pubitemid 27453879)
11. Fassas, A.; Buffels, R.; Anagnostopoulos, A.; Gacos, E.; Vadikolia, C.; Haloudis, P.; Kaloyannidis, P. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. Br. J. Haematol., 2002, 116(2), 308-315. (Pubitemid 34155501)
12. Maeda, H.; Wu, J.; Sawa, T., Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release, 2000, 65 (1-2), 271-284. (Pubitemid 30122932)
13. Allen, T. M., Cullis, P. R. Drug delivery systems: entering the mainstream. Science, 2004, 303(5665), 1818-1822. (Pubitemid 38374867)
14. Young, R. C.; Ozols, R. F.; Myers, C. E. The anthracycline antineoplastic drugs. N. Engl. J. Med., 1981, 305(3), 139-153. (Pubitemid 11073081)
15. Chaires, J. B.; Herrera, J. E.; Waring, M. J. Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments. Biochemistry, 1990, 29(26), 6145-6153. (Pubitemid 20222228)
16. Minotti, G., Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56(2), 185-229. (Pubitemid 38720829)
17. Binaschi, M.; Bigioni, M.; Cipollone, A.; Rossi, C.; Goso, C.; Maggi, C. A.; Capranico, G.; Animati, F. Anthracyclines: selected new developments. Curr. Med. Chem. Anticancer Agents, 2001, 1(2), 113-30.
18. Dalton, W. S. Mechanisms of drug resistance in hematologic malignancies. Semin. Hematol., 1997, 34 (4 Suppl 5), 3-8. (Pubitemid 28032414)
19. Michieli, M.; Damiani, D.; Ermacora, A.; Masolini, P.; Michelutti, A.; Michelutti, T.; Russo, D.; Pea, F.; Baccarani, M. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br. J. Haematol., 1999, 106(1), 92-99. (Pubitemid 29343532)
20. Rahman, A.; Husain, S. R.; Siddiqui, J.; Verma, M.; Agresti, M.; Center, M.; Safa, A. R.; Glazer, R. I. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl. Cancer Inst., 1992, 84(24), 1909-1915.
21. Liu, F. T., Kelsey, S. M.; Newland, A. C.; Jia, L. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells. Br. J. Haematol., 2002, 117(2), 333-342. (Pubitemid 34451148)
22. Latagliata, R.; Breccia, M.; Fazi, P.; Iacobelli, S.; Martinelli, G.; Di Raimondo, F.; Sborgia, M.; Fabbiano, F.; Pirrotta, M. T.; Zaccaria, A.; Amadori, S.; Caramatti, C.; Falzetti, F.; Candoni, A.; Mattei, D.; Morselli, M.; Alimena, G.; Vignetti, M.; Baccarani, M.; Mandelli, F. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br. J. Haematol., 2008, 143(5), 681-689.
23. Greenaway, F. T.; Dabrowiak, J. C.; The binding of copper ions to daunomycin and adriamycin. J. Inorg. Biochem., 1982, 16, 91-107. (Pubitemid 13015227)
24. Tardi, P.; Johnstone, S.; Harasym, N.; Xie, S.; Harasym, T.; Zisman, N.; Harvie, P.; Bermudes, D.; Mayer, L. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res., 2009, 33(1), 129-139.
25. Galmarini, C. M.; Popowycz, F.; Joseph, B. Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Curr. Med. Chem., 2008, 15(11), 1072-1082. (Pubitemid 352002976)
26. Bergman, A. M.; Kuiper, C. M.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters, G. J. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids, 2004, 23 (8-9), 1523-1526. (Pubitemid 39625956)
27. Bergman, A. M.; Kuiper, C. M.; Voorn, D. A.; Comijn, E. M.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters, G. J. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem. Pharmacol., 2004, 67(3), 503-511. (Pubitemid 38232890)
28. Galmarini, C. M.; Myhren, F.; Sandvold, M. L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br. J. Haematol., 2009, 144(2), 273-275.
29. Adams, D. J.; Sandvold, M. L.; Myhren, F., Jacobsen, T. F.; Giles, F.; Rizzieri, D. A. Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk. Lymphoma., 2008, 49(4), 786-797. (Pubitemid 351517226)
30. Bonate, P. L.; Arthaud, L.; Cantrell, W. R. Jr.; Stephenson, K.; Secrist, J. A. 3rd; Weitman, S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat. Rev. Drug Discov., 2006, 5(10), 855-863. (Pubitemid 44480539)
31. Van den Neste, E.; Cardoen, S.; Offner, F.; Bontemps, F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int. J. Oncol. 2005, 27(4), 1113-1124.
32. Parker, W. B.; Shaddix, S. C.; Chang, C. H.; White, E. L.; Rose, L. M.; Brockman, R. W.; Shortnacy, A. T.; Montgomery, J. A.; Secrist, J. A. 3rd.; Bennett, L. L. Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res., 1991, 51(9), 2386-2394.
33. Avramis, V. I.; Plunkett, W. Metabolism of 9-beta-D-arabinosyl-2- fluoroadenine-5'-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv., 1983, 1(1), 1-10. (Pubitemid 15188060)
34. Kantarjian, H. M.; Gandhi, V.; Kozuch, P.; Faderl, S.; Giles, F.; Cortes, J.; O'Brien, S.; Ibrahim, N.; Khuri, F.; Du, M.; Rios, M. B.; Jeha, S.; McLaughlin, P.; Plunkett, W.; Keating, M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol., 2003, 21(6), 1167-1173. (Pubitemid 46594149)
35. Kantarjian, H.; Gandhi, V.; Cortes, J.; Verstovsek, S.; Du, M.; Garcia-Manero, G.; Giles, F.; Faderl, S.; O'Brien, S.; Jeha, S.; Davis, J.; Shaked, Z.; Craig, A.; Keating, M.; Plunkett, W.; Freireich, E. J. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 2003, 102(7), 2379-2386. (Pubitemid 37193573)
36. Faderl, S.; Verstovsek, S.; Cortes, J.; Ravandi, F.; Beran, M.; Garcia-Manero, G.; Ferrajoli, A.; Estrov, Z.; O'Brien, S.; Koller, C.; Giles, F. J.; Wierda, W.; Kwari, M.; Kantarjian, H. M. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood, 2006, 108(1), 45-51. (Pubitemid 43990611)
37. Faderl, S.; Ravandi, F.; Huang, X.; Garcia-Manero, G.; Ferrajoli, A.; Estrov, Z.; Borthakur, G.; Verstovsek, S.; Thomas, D. A.; Kwari, M.; Kantarjian, H. M. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2008, 112(5), 1638-1645.
38. Faderl, S.; Ferrajoli, A.; Wierda, W.; Huang, X.; Verstovsek, S.; Ravandi, F.; Estrov, Z.; Borthakur, G.; Kwari, M.; Kantarjian, H. M. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer, 2008, 113(8), 2090-2096.
39. Kukhanova, M.; Liu, S. H.; Mozzherin, D.; Lin, T. S.; Chu, C. K.; Cheng, Y. C. L-and D-enantiomers of 2', 3'-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J. Biol. Chem., 1995, 270(39), 23055-23059.
40. Moore, L. E.; Boudinot, F. D., Chu, C. K. Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother. Pharmacol., 1997, 39(6), 532-536. (Pubitemid 27096769)
41. Giles, F. J.; Cortes, J. E.; Baker, S. D.; Thomas, D. A.; O'Brien, S.; Smith, T. L.; Beran, M.; Bivins, C.; Jolivet, J.; Kantarjian, H. M. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J. Clin. Oncol., 2001, 19(3), 762-771. (Pubitemid 32119091)
42. Giles, F. J.; Faderl, S.; Thomas, D. A.; Cortes, J. E.; Garcia-Manero, G.; Douer, D.; Levine, A. M.; Koller, C. A.; Jeha, S. S.; O'Brien, S. M.; Estey, E. H.; Kantarjian, H. M. Randomized phase I/II study of troxacytabine combined with cytarabine, idarubicin or topotecan in patients with refractory myeloid leukemias. J. Clin. Oncol., 2003, 21(6), 1050-1056. (Pubitemid 46594134)
43. Giles, F. J.; Kantarjian, H. M.; Cortes, J. E.; Garcia-Manero, G.; Verstovsek, S.; Faderl, S.; Thomas, D. A., Ferrajoli, A.; O'Brien, S.; Wathen, J. K.; Xiao, L. C.; Berry, D. A.; Estey, E. H. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J. Clin. Oncol., 2003, 21(9), 1722-1727. (Pubitemid 46638583)
44. Roboz, G. J.; Giles, F. J.; Ritchie, E. K.; Allen-Bard, S.; Curcio, T. J.; Wilkes, M. A.; Park, S. L.; Kantarjian, H. M.; Faderl, S.; Ravandi, F.; Kelner, M. J.; Feldman, E. J. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J. Clin. Oncol., 2007, 25(1), 10-15. (Pubitemid 350003045)
45. Serova, M.; Galmarini, C. M.; Ghoul, A.; Benhadji, K.; Green, S. R.; Chiao, J.; Faivre, S.; Cvitkovic, E.; Le Tourneau, C.; Calvo, F.; Raymond, E. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine- derivative, in human cancer cells. Br. J. Cancer., 2007, 97(5), 628-636. (Pubitemid 47339878)
46. Hanaoka, K.; Suzuki, M.; Kobayashi, T.; Tanzawa, F.; Tanaka, K.; Shibayama, T.; Miura, S.; Ikeda, T.; Iwabuchi, H.; Nakagawa, A.; Mitsuhashi, Y.; Hisaoka, M.; Kaneko, M.; Tomida, A.; Wataya, Y.; Nomura, T.; Sasaki, T.; Matsuda, A.; Tsuruo, T.; Kurakata, S. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D- arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Int. J. Cancer, 1999, 82(2), 226-236. (Pubitemid 29293782)
47. Kantarjian, H.; Garcia-Manero, G.; O'Brien, S.; Faderl, S.; Ravandi, F.; Westwood, R.; Green, S. R.; Chiao, J. H., Boone, P. A.; Cortes, J.; Plunkett, W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J. Clin. Oncol., 2010, 28(2), 285-291.
48. Quesnel, B.; Fenaux, P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma., 1999, 35 (5-6), 437-443. (Pubitemid 30015643)
49. Baylin, S. B.; Fearon, E. R.; Vogelstein, B.; de Bustros, A.; Sharkis, S. J.; Burke, P. J.; Staal, S. P., Nelkin, B. D. Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood, 1987, 70(2), 412-417. (Pubitemid 17142924)
50. Dhodapkar, M.; Grill, J.; Lust, J. A. Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes. Leuk. Res., 1995, 19(10), 719-726.
51. Daskalakis, M.; Nguyen, T. T.; Nguyen, C.; Guldberg, P.; Kohler, G.; Wijermans, P.; Jones, P. A.; Lubbert, M. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'- deoxycytidine (decitabine) treatment. Blood, 2002, 100(8), 2957-2964.
52. Quesnel, B.; Guillerm, G.; Vereecque, R.; Wattel, E.; Preudhomme, C.; Bauters, F.; Vanrumbeke, M.; Fenaux, P. Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 1998, 91(8), 2985-2990. (Pubitemid 28227550)
53. Tien, H. F.; Tang, J. H.; Tsay, W.; Liu, M. C.; Lee, F. Y.; Wang, C. H., Chen, Y. C.; Shen, M. C. Methylation of the p15 (INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br. J. Haematol., 2001, 112(1), 148-154. (Pubitemid 32151162)
54. Saiki, J. H.; McCredie, K. B.; Vietti, T. J.; Hewlett, J. S.; Morrison, F. S.; Costanzi, J. J.; Stuckey, W. J.; Whitecar, J.; Hoogstraten, B. 5-azacytidine in acute leukemia. Cancer, 1978, 42(5), 2111-2114.
55. Garcia-Manero, G. Demethylating agents in myeloid malignancies. Curr. Opin. Oncol., 2008, 20(6), 705-710.
56. Kuendgen, A.; Germing, U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat. Rev., 2009, 35(2), 97-120.
57. Marcucci, G.; Silverman, L.; Eller, M.; Lintz, L.; Beach, C. L. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J. Clin. Pharmacol, 2005, 45(5), 597-602. (Pubitemid 40562951)
58. Fenaux, P.; Mufti, G. J.; Hellstrom-Lindberg, E.; Santini, V.; Finelli, C.; Giagounidis, A.; Schoch, R.; Gattermann, N.; Sanz, G.; List, A.; Gore, S. D.; Seymour, J. F.; Bennett, J. M.; Byrd, J.; Backstrom, J.; Zimmerman, L.; McKenzie, D.; Beach, C.; Silverman, L. R. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol., 2009, 10(3), 223-232.
59. Sudan, N.; Rossetti, J. M.; Shadduck, R. K.; Latsko, J.; Lech, J. A.; Kaplan, R. B.; Kennedy, M.; Gryn, J. F.; Faroun, Y.; Lister, J. Treatment of acute yelogenous leukemia with outpatient azacitidine. Cancer, 2006, 107(8), 1839-1843. (Pubitemid 44582953)
60. Gore, S. D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C. B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J. E.; Rudek, M. A.; Zhao, M.; Smith, B. D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L. J.; Herman, J. G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res., 2006, 66(12), 6361-6369.
61. Silverman, L. R.; McKenzie, D. R.; Peterson, B. L.; Holland, J. F.; Backstrom, J. T.; Beach, C. L.; Larson, R. A. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol., 2006, 24(24), 3895-3903. (Pubitemid 46630737)
62. Hollenbach, P. W.; Nguyen, A. N.; Brady, H.; Williams, M.; Ning, Y.; Richard, N.; Krushel, L.; Aukerman, S. L.; Heise, C.; MacBeth, K. J. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One, 2010, 5(2), 9001.
63. Blum, W.; Klisovic, R. B.; Hackanson, B.; Liu, Z.; Liu, S.; Devine, H.; Vukosavljevic, T.; Huynh, L.; Lozanski, G.; Kefauver, C.; Plass, C.; Devine, S. M.; Heerema, N. A.; Murgo, A.; Chan, K. K.; Grever, M. R.; Byrd, J. C.; Marcucci, G. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol., 2007, 25(25), 3884-3891. (Pubitemid 47477265)
64. Garcia-Manero, G.; Kantarjian, H. M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W. G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'Brien, S.; Estey, E.; Bueso-Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J. P. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood, 2006, 108(10), 3271-3279.
65. Gray, S. G.; Ekstrom, T. J. The human histone deacetylase family. Exp. Cell Res., 2001, 262(2), 75-83. (Pubitemid 32980246)
66. Ropero, S.; Esteller, M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol., 2007, 1(1), 19-25. (Pubitemid 46776612)
67. Shankar, S.; Srivastava, R. K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitorinduced apoptosis. Adv. Exp. Med. Biol., 2008, 615, 261-298.
68. Marks, P. A.; Jiang, X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle, 2005, 4(4), 549-551. (Pubitemid 41359778)
69. Fabre, C.; Grosjean, J.; Tailler, M.; Boehrer, S.; Ades, L.; Perfettini, J. L.; de Botton, S.; Fenaux, P.; Kroemer, G. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle, 2008, 7(14), 2139-2145. (Pubitemid 352031516)
70. Kramer, O. H.; Zhu, P.; Ostendorff, H. P.; Golebiewski, M.; Tiefenbach, J.; Peters, M. A.; Brill, B.; Groner, B.; Bach, I.; Heinzel, T.; Gottlicher, M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J., 2003, 22(13), 3411-3420. (Pubitemid 36834871)
71. Ferrara, F. F.; Fazi, F.; Bianchini, A.; Padula, F.; Gelmetti, V.; Minucci, S.; Mancini, M.; Pelicci, P. G.; Lo-Coco, F.; Nervi, C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 2001, 61(1), 2-7. (Pubitemid 32095688)
72. Cimino, G.; Lo-Coco F.; Fenu, S.; Travaglini, L.; Finolezzi, E.; Mancini, M.; Nanni, M.; Careddu, A.; Fazi, F.; Padula, F.; Fiorini, R.; Spiriti, M. A.; Petti, M. C.; Venditti, A.; Amadori, S.; Mandelli, F.; Pelicci, P. G., Nervi, C. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res., 2006, 66(17), 8903-8911. (Pubitemid 44449209)
73. Bug, G.; Schwarz, K.; Schoch, C.; Kampfmann, M.; Henschler, R.; Hoelzer, D.; Ottmann, O. G.; Ruthardt, M. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica., 2007, 92(4), 542-545. (Pubitemid 350144299)
74. Lech-Maranda, E.; Robak, E.; Korycka, A.; Robak, T. Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity. Mini Rev. Med. Chem., 2007, 7(10), 1062-1069. (Pubitemid 47554775)
75. Klimek, V. M.; Fircanis, S.; Maslak, P.; Guernah, I.; Baum, M.; Wu, N.; Panageas, K.; Wright, J. J.; Pandolfi, P. P.; Nimer, S. D. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer. Res., 2008, 14(3), 826-832. (Pubitemid 351231166)
76. Siegel, D.; Hussein, M.; Belani, C.; Robert, F.; Galanis, E.; Richon, V. M.; Garcia-Vargas, J.; Sanz-Rodriguez, C.; Rizvi, S. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol., 2009, 2, 31.
77. Munster, P. N.; Troso-Sandoval, T.; Rosen, N.; Rifkind, R.; Marks, P. A.; Richon, V. M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 2001, 61(23), 8492-8497. (Pubitemid 33131130)
78. Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad Sci. USA, 1996, 93(12), 5705-5708. (Pubitemid 26191313)
79. Mitsiades, N.; Mitsiades, C. S.; Richardson, P. G.; McMullan, C.; Poulaki, V.; Fanourakis, G.; Schlossman, R.; Chauhan, D.; Munshi, N. C.; Hideshima, T.; Richon, V. M., Marks, P. A.; Anderson, K. C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 2003, 101(10), 4055-4062. (Pubitemid 36857886)
80. Ruefli, A. A.; Ausserlechner, M. J.; Bernhard, D.; Sutton, V. R.; Tainton, K. M.; Kofler, R.; Smyth, M. J.; Johnstone, R. W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad Sci. USA, 2001, 98(19), 10833-10838. (Pubitemid 32878706)
81. Kelly, W. K.; O'Connor, O. A.; Krug, L. M.; Chiao, J. H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J. P.; Schwartz, L.; Richardson, S.; Chu, E.;, Olgac, S.; Marks, P. A.; Scher, H.; Richon, V. M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol., 2005, 23(17), 3923-3931. (Pubitemid 46218695)
82. Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; Wierda, W. G.; Faderl, S.; Koller, C.; Morris, G.; Rosner, G.; Loboda, A.; Fantin, V. R. Randolph, S. S.; Hardwick, J. S.; Reilly, J. F.; Chen, C.; Ricker, J. L.; Secrist, J. P.; Richon, V. M.; Frankel, S. R.; Kantarjian, H. M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 2008, 111(3), 1060-1066. (Pubitemid 351213383)
83. Schaefer, E. W.; Loaiza-Bonilla, A.; Juckett, M.; DiPersio, J. F.; Roy, V.; Slack, J.; Wu, W.; Laumann, K.; Espinoza-Delgado, I.; Gore, S. D. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica., 2009, 94(10), 1375-1382.
84. Fournel, M.; Bonfils, C.; Hou, Y.; Yan, P. T.; Trachy-Bourget, M. C.; Kalita, A.; Liu, J.; Lu, A. H.; Zhou, N. Z.; Robert, M. F.; Gillespie, J.; Wang, J. J.; Ste-Croix, H.; Rahil, J.; Lefebvre, S.; Moradei, O.; Delorme, D.; Macleod, A. R.; Besterman, J. M.; Li, Z. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther., 2008, 7(4), 759-768. (Pubitemid 351551029)
85. Garcia-Manero, G.; Assouline, S.; Cortes, J.; Estrov, Z.; Kantarjian, H.; Yang, H.; Newsome, W. M.; Miller, W. H. Jr.; Rousseau, C.; Kalita, A.; Bonfils, C.; Dubay, M.; Patterson, T. A.; Li, Z.; Besterman, J. M.; Reid, G.; Laille, E.; Martell, R. E.; Minden, M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 2008, 112(4), 981-989.
86. Gao, S.; Mobley, A.; Miller, C.; Boklan, J.; Chandra, J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk. Res., 2008, 32(5), 771-780. (Pubitemid 351323931)
87. Gojo, I.; Jiemjit, A.; Trepel, J. B.; Sparreboom, A.; Figg, W. D.; Rollins, S.; Tidwell, M. L.; Greer, J.; Chung, E. J.; Lee, M. J.; Gore, S. D.; Sausville, E. A.; Zwiebel, J.; Karp, J. E. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood, 2007, 109(7), 2781-2790. (Pubitemid 46482071)
88. George, P.; Bali, P.; Annavarapu, S.; Scuto, A.; Fiskus, W.; Guo, F.; Sigua, C.; Sondarva, G.; Moscinski, L.; Atadja, P.; Bhalla, K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood, 2005, 105(4), 1768-1776. (Pubitemid 40223701)
89. Maiso, P.; Colado, E.; Ocio, E. M.; Garayoa, M.; Martin, J.; Atadja, P.; Pandiella, A.; San-Miguel, J. F. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia, 2009, 23(12), 2265-2274.
90. Vey, N.; Giles, F. Laromustine (cloretazine). Expert Opin. Pharmacother., 2010, 11(4), 657-667.
91. Pigneux, A. Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy. Drugs, 2009, 12(1), 39-53.
92. Morris, K. L.; Adams, J. A.; Liu Yin, J. A. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin. Leuk. Res., 2009, 33(8), 1096-1099.
93. Giles, F.; Verstovsek, S.; Thomas, D.; Gerson, S.; Cortes, J.; Faderl, S.; Ferrajoli, A.; Ravandi, F.; Kornblau, S.; Garcia-Manero, G.; Jabbour, E.; O'Brien, S.; Karsten, V.; Cahill, A.; Yee, K.; Albitar, M.; Sznol, M.; Kantarjian, H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin. Cancer Res., 2005, 11(21), 7817-7824. (Pubitemid 41611626)
94. Giles, F.; Thomas, D.; Garcia-Manero, G.; Faderl, S.; Cortes, J.; Verstovsek, S.; Ferrajoli, A.; Jeha, S.; Beran, M.; Koller, C.; Andreeff, M.; Cahill, A.; Clairmont, C.; Sznol, M.; Kantarjian, H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin. Cancer Res., 2004, 10(9), 2908-2917. (Pubitemid 38619664)
95. Braun, T.; Fenaux, P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol., 2008, 141(5), 576-586. (Pubitemid 351667628)
96. Carpenter, C. L.; Cantley, L. C. Phosphoinositide kinases. Curr. Opin Cell Biol., 1996, 8(2), 153-8. (Pubitemid 26109087)
97. Hagemann, C.; Blank, J. L. The ups and downs of MEK kinase interactions. Cell Signal, 2001, 13(12), 863-875. (Pubitemid 33139788)
98. Philips, M. R.; Cox, A. D. Geranylgeranyl transferase I as a target for anti-cancer drugs. J. Clin. Invest., 2007, 117(5), 1223-1225. (Pubitemid 46718409)
99. Gore, S. D.; Hermes-DeSantis, E. R. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control, 2008, 15, 40-49.
100. Korycka, A.; Smolewski, P.; Robak, T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur. J. Haematol., 2004, 73(6), 418-426. (Pubitemid 39564365)
101. Karp, J. E.; Lancet, J. E.; Kaufmann, S. H.; End, D. W.; Wright, J. J.; Bol, K.; Horak, I.; Tidwell, M. L.; Liesveld, J.; Kottke, T. J.; Ange, D.; Buddharaju, L.; Gojo, I.; Highsmith, W. E.; Belly, R. T.; Hohl, R. J.; Rybak, M. E.; Thibault A, Rosenblatt, J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinicallaboratory correlative trial. Blood, 2001, 97(11), 3361-3369.
102. Lancet, J. E.; Gojo, I.; Gotlib, J.; Feldman, E. J.; Greer, J.; Liesveld, J. L.; Bruzek, L. M.; Morris, L.; Park, Y.; Adjei, A. A.; Kaufmann, S. H.; Garrett-Mayer, E.; Greenberg, P. L.; Wright, J. J.; Karp, J. E. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poorrisk and elderly patients with previously untreated acute myelogenous leukemia. Blood, 2007, 109(4), 1387-1394. (Pubitemid 46242109)
103. Harousseau, J. L.; Martinelli, G.; Jedrzejczak, W. W.; Brandwein, J. M.; Bordessoule, D.; Masszi, T.; Ossenkoppele, G. J.; Alexeeva, J. A.; Beutel, G.; Maertens, J.; Vidriales, M. B.; Dombret, H.; Thomas, X.; Burnett, A. K.; Robak, T.; Khuageva, N. K.; Golenkov, A. K.; Tothova, E.; Mollgard, L.; Park, Y. C.; Bessems, A.; De Porre, P.; Howes, A. J. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood, 2009, 114(6), 1166-1173.
104. Karp, J. E.; Smith, B. D.; Gojo, I.; Lancet, J. E.; Greer, J.; Klein, M.; Morris, L.; Levis, M. J.; Gore, S. D.; Wright, J. J.; Garrett-Mayer, E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin. Cancer Res., 2008, 14(10), 3077-3082.
105. Karp, J. E.; Flatten, K.; Feldman, E. J.; Greer, J. M.; Loegering, D. A.; Ricklis, R. M.; Morris, L. E.; Ritchie, E.; Smith, B. D.; Ironside, V.; Talbott, T.; Roboz, G.; Le, S. B.; Meng, X. W.; Schneider, P. A.; Dai, N. T.; Adjei, A. A.; Gore, S. D.; Levis, M. J.; Wright, J. J.; Garrett-Mayer, E.; Kaufmann, S. H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood, 2009, 113(20), 4841-4852.
106. Ravoet, C.; Mineur, P.; Robin, V.; Debusscher, L.; Bosly, A.; Andre, M.; El Housni, H.; Soree, A.; Bron, D.; Martiat, P. Farnesyltransferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann. Hematol., 2008, 87(11), 881-885.
107. Feldman, E. J.; Cortes, J.; DeAngelo, D. J.; Holyoake, T.; Simonsson, B.; O'Brien, S. G.; Reiffers, J.; Turner, A. R.; Roboz, G. J.; Lipton, J. H.; Maloisel, F.; Colombat, P.; Martinelli, G.; Nielsen, J. L.; Petersdorf, S.; Guilhot, F.; Barker, J.; Kirschmeier, P.; Frank, E.; Statkevich, P.; Zhu, Y.; Loechner, S.; List, A. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia, 2008, 22(9), 1707-1711.
108. Liu, M.; Bryant, M. S.; Chen, J.; Lee, S.; Yaremko, B.; Lipari, P.; Malkowski, M.; Ferrari, E.; Nielsen, L.; Prioli, N.; Dell, J.; Sinha, D.; Syed, J.; Korfmacher, W. A.; Nomeir, A. A.; Lin, C. C.; Wang, L.; Taveras, A. G.; Doll, R. J.; Njorog, F. G.; Mallams, A. K.; Remiszewski, S.; Catino, J. J.; Girijavallabhan, V. M.; Bishop, W. R.; et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res., 1998, 58(21), 4947-4956. (Pubitemid 28503695)
109. Taylor, S. A.; Marrinan, C. H.; Liu, G.; Nale, L.; Bishop, W. R.; Kirschmeier, P.; Liu, M.; Long, B. J. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo. Gynecol. Oncol., 2008, 109(1), 97-106.
110. Rose W. C.; Lee, F. Y.; Fairchild, C. R.; Lynch, M.; Monticello, T.; Kramer, R. A.; Manne, V. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res., 2001, 61(20), 7507-7517. (Pubitemid 32995041)
111. Pellicano, F.; Copland, M.; Jorgensen, H. G.; Mountford, J.; Leber, B.; Holyoake, T. L. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38-cells, through activation of protein kinase Cbeta. Blood, 2009, 114(19), 4186-4196.
112. Copland, M.; Pellicano, F.; Richmond, L.; Allan, E. K.; Hamilton, A.; Lee, F. Y.; Weinmann, R.; Holyoake, T. L. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, 111(5), 2843-2853.
113. Erratum in: Blood, 2008, 111(9), 4830.
114. Cortes, J.; Faderl, S.; Estey, E.; Kurzrock, R.; Thomas, D.; Beran, M.;
115. Mrozek, K.; Marcucci, G.; Paschka, P.; Whitman, S. P.; Bloomfield, C. D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, 2007, 109(2), 431-448. (Pubitemid 46105936)
116. Sanz, M.; Burnett, A.; Lo-Coco, F.; Lowenberg, B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr. Opin. Oncol., 2009, 21(6), 594-600.
117. Frohling, S.; Schlenk, R. F.; Breitruck, J.; Benner, A.; Kreitmeier, S.; Tobis, K.; Dohner, H.; Dohner, K. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 2002, 100(13), 4372-4380. (Pubitemid 35434129)
118. Brown, P.; Meshinchi, S.; Levis, M.; Alonzo, T. A.; Gerbing, R.; Lange, B.; Arcec, R.; Small, D. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood, 2004, 104(6), 1841-1849. (Pubitemid 39202295)
119. Smith, B. D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, K. M.; Dauses, T.; Allebach, J.; Small, D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 2004, 103(10), 3669-3976.
120. Knapper, S.; Burnett, A. K.; Littlewood, T.; Kell, W. J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M. J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108(10), 3262-3270.
121. Knapper, S.; Mills, K. I.; Gilkes, A. F.; Austin, S. J.; Walsh, V.; Burnett, A. K. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood, 2006, 108(10), 3494-3503.
122. Li, H.; Herger, S. M.; Schafer, S. C.; Brausch, I.; Yao, Y.; Huang, Q.; Mang, C.; Lehr, H. A.; Forstermann, U. Midostaurin upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse. Nitric Oxide, 2005, 12(4), 231-236. (Pubitemid 40732392)
123. Stone, R. M.; DeAngelo, D. J.; Klimek, V.; Galinsky, I.; Estey, E.; Nimer, S. D.; Grandin, W.; Lebwohl, D.; Wang, Y.; Cohen, P.; Fox, E. A.; Neuberg, D.; Clark, J.; Gilliland, D. G.; Griffin, J. D. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005, 105(1), 54-60. (Pubitemid 40053063)
124. Cheng, Y.; Paz, K. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications. Drugs, 2008, 11(1), 46-56.
125. Schittenhelm, M. M.; Kampa, K. M.; Yee, K. W.; Heinrich, M. C. The FLT3 inhibitor tandutinib (formerly MLN518) has sequenceindependent synergistic effects with cytarabine and daunorubicin. Cell Cycle, 2009, 8(16), 2621-2630.
126. DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B. J.; Heinrich, M. C. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood, 2006, 108(12), 3674-3681. (Pubitemid 44864544)
127. O'Farrell, A. M.; Abrams, T. J.; Yuen, H. A.; Ngai, T. J.; Louie, S. G.; Yee, K. W.; Wong, L. M.; Hong, W.; Lee, L. B.; Town, A.; Smolich, B. D.; Manning, W. C.; Murray, L. J.; Heinrich, M. C.; Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003, 101(9), 3597-3605. (Pubitemid 36857948)
128. O'Farrell, A. M.; Foran, J. M.; Fiedler, W.; Serve, H.; Paquette, R. L.; Cooper, M. A.; Yuen, H. A.; Louie, S. G.; Kim, H.; Nicholas, S.; Heinrich, M. C.; Berdel, W. E.; Bello, C.; Jacobs, M.; Scigalla, P.; Manning, W. C.; Kelsey, S.; Cherrington, J. M. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res., 2003, 9(15), 5465-5476. (Pubitemid 37499464)
129. Escudier, B.; Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther., 2010, 10(3), 305-317.
130. Fiedler, W.; Serve, H.; Dohner, H.; Schwittay, M.; Ottmann, O. G.; O'Farrell, A. M.; Bello, C. L.; Allred, R.; Manning, W. C.; Cherrington, J. M.; Louie, S. G.; Hong, W.; Brega, N. M.; Massimini, G.; Scigalla, P.; Berdel, W. E.; Hossfeld, D. K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005, 105(3), 986-993. (Pubitemid 40170865)
131. Yee, K. W.; Schittenhelm, M.; O'Farrell, A. M.; Town, A. R.; McGreevey, L.; Bainbridge, T.; Cherrington, J. M.; Heinrich, M. C. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood, 2004, 104(13), 4202-4209. (Pubitemid 39620175)
132. Yee, K. W.; O'Farrell, A. M.; Smolich, B. D.; Cherrington, J. M.; McMahon, G.; Wait, C. L.; McGreevey, L. S.; Griffith, D. J.; Heinrich, M. C. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 2002, 100(8), 2941-2949.
133. Giles, F. J.; Stopeck, A. T.; Silverman, L. R.; Lancet, J. E.; Cooper, M. A.; Hannah, A. L.; Cherrington, J. M.; O'Farrell, A. M.; Yuen, H. A.; Louie, S. G.; Hong, W.; Cortes, J. E.; Verstovsek, S.; Albitar, M.; O'Brien, S. M.; Kantarjian, H. M.; Karp, J. E. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood, 2003, 102(3), 795-801. (Pubitemid 36917765)
134. Fiedler, W.; Mester, R.; Tinnefeld, H.; Loges, S.; Staib, P.; Duhrsen, U.; Flasshove, M.; Ottmann, O. G.; Jung, W.; Cavalli, F.; Kuse, R.; Thomalla, J.; Serve, H.; O'Farrell, A. M., Jacobs, M.; Brega, N. M.; Scigalla, P.; Hossfeld, D. K.; Berdel, W. E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 2003, 102(8), 2763-2767. (Pubitemid 37248845)
135. Lee, J. T. Jr.; McCubrey, J. A. Targeting the Raf kinase cascade in cancer therapy-novel molecular targets and therapeutic strategies. Expert Opin. Ther. Targets, 2002, 6(6), 659-678. (Pubitemid 36054578)
136. Lee, J. T. Jr.; McCubrey, J. A. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia, 2002, 16(4), 486-507. (Pubitemid 34449728)
137. Zhang, W.; Konopleva, M.; Ruvolo, V. R.; McQueen, T.; Evans, R. L.; Bornmann, W. G.; McCubrey, J.; Cortes, J.; Andreeff, M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia, 2008, 22(4), 808-818. (Pubitemid 351552630)
138. Zhang, W.; Konopleva, M.; Shi, Y. X.; McQueen, T.; Harris, D.; Ling, X.; Estrov, Z.; Quintas-Cardama, A.; Small, D.; Cortes, J.; Andreeff, M. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J. Natl. Cancer Inst., 2008, 100(3), 184-198. (Pubitemid 351480557)
139. Crump, M.; Hedley, D.; Kamel-Reid, S.; Leber, B.; Wells, R.; Brandwein, J.; Buckstein, R.; Kassis, J.; Minden, M.; Matthews, J.; Robinson, S.; Turner, R.; McIntosh, L.; Eisenhauer, E.; Seymour, L. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk. Lymphoma., 2010, 51(2), 252-260.
140. Ravandi, F.; Cortes, J. E.; Jones, D.; Faderl, S.; Garcia-Manero, G.; Konopleva, M. Y.; O'Brien, S.; Estrov, Z.; Borthakur, G.; Thomas, D.; Pierce, S. R.; Brandt, M.; Byrd, A.; Bekele, B. N.; Pratz, K.; Luthra, R.; Levis, M.; Andreeff, M.; Kantarjian, H. M. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J. Clin. Oncol., 2010, 28(11), 1856-1862.
141. Boissel, N.; Leroy, H.; Brethon, B.; Philippe, N.; de Botton, S.; Auvrignon,; Raffoux, E.; Leblanc, T.; Thomas, X.; Hermine, O.; Quesnel, B.; Baruchel, A.; Leverger, G.; Dombret, H.; Preudhomme, C. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia, 2006, 20(6), 965-970. (Pubitemid 43797286)
142. Nanri, T.; Matsuno, N.; Kawakita, T.; Suzushima, H.; Kawano, F.; Mitsuya, H.; Asou, N. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t (8;21) (q22;q22). Leukemia, 2005, 19(8), 1361-1366. (Pubitemid 41136329)
143. Kohl, TM.; Schnittger, S.; Ellwart, J. W.; Hiddemann, W.; Spiekermann, K. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood, 2005, 105(8), 3319-3321.
144. Mauro, M. J.; Druker, B. J. STI571: a gene product-targeted therapy for leukemia. Curr. Oncol. Rep., 2001, 3(3), 223-227.
145. Chevallier, P.; Hunault-Berger, M.; Larosa, F.; Dauriac, C.; Garand, R.; Harousseau, J. L. A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. Leuk. Res., 2009, 33(8), 1124-1126.
146. Scappini, B.; Onida, F.; Kantarjian, H. M.; Dong, L.; Verstovsek, S.; Keating, M. J.; Beran, M. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin. Cancer Res., 2001, 7(12), 3884-3893. (Pubitemid 34044605)
147. Fang, G.; Kim, C. N.; Perkins, C. L.; Ramadevi, N.; Winton, E.; Wittmann, S.; Bhalla, K. N. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 2000, 96(6), 2246-2253.
148. Walker, A. R.; Komrokji, R. S.; Ifthikharuddin, J.; Messina, P.; Mulford, D.; Becker, M.; Friedberg, J.; Oliva, J.; Phillips, G.; Liesveld, J. L.; Abboud, C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk. Res., 2008, 32(12), 1830-1836.
149. Heidel, F.; Cortes, J.; Rucker, F. G.; Aulitzky, W.; Letvak, L.; Kindler, T.; Huber, C.; Dohner, H.; Kantarjian, H.; Fischer, T. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer, 2007, 109(5), 907-914. (Pubitemid 46335678)
150. Doggrell, S. A. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opin. Investig. Drugs, 2005, 14(1), 89-91.
151. Schittenhelm, M. M.; Shiraga, S.; Schroeder, A.; Corbin, A. S.; Griffith, D.; Lee, F. Y.; Bokemeyer, C.; Deininger, M. W.; Druker, B. J.; Heinrich, M. C. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res., 2006, 66(1), 473-481. (Pubitemid 43166056)
152. Guerrouahen, B. S.; Futami, M.; Vaklavas, C.; Kanerva, J.; Whichard, Z. L.; Nwawka, K.; Blanchard, E. G., Lee, F. Y.; Robinson, L. J.; Arceci, R.; Kornblau, S. M.; Wieder, E.; Cayre, Y. E.; Corey, S. J. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin. Cancer Res., 2010, 16(4), 1149-1158.
153. Kelly, R. J.; Rixe, O. Axitinib (AG-013736). Recent Results Cancer Res. 2010, 184, 33-44.
154. Giles, F. J.; Bellamy, W. T.; Estrov, Z.; O'Brien, S. M.; Verstovsek, S.; Ravandi, F.; Beran, M.; Bycott, P.; Pithavala, Y.; Steinfeldt, H.; Reich, S. D.; List, A. F.; Yee, K. W. The anti-angiogenesis agent, AG-013736, has minimal activity in lderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk. Res., 2006, 30(7), 801-811. (Pubitemid 43816694)
155. Recher, C.; Beyne-Rauzy, O.; Demur, C.; Chicanne, G.; Dos Santos, C.; Mas, V. M.; Benzaquen, D.; Laurent, G.; Huguet, F.; Payrastre, B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 2005, 105(6), 2527-2534. (Pubitemid 40387055)
156. Smolewski, P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin. Investig. Drugs, 2006, 15(10), 1201-1227. (Pubitemid 44608260)
157. Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature, 1994, 369(6483), 756-758.
158. Janus, A.; Robak, T.; Smolewski, P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol. Biol. Lett., 2005, 10(3), 479-498. (Pubitemid 41564520)
159. Costa, L. J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev., 2007, 33(1), 78-84. (Pubitemid 46132007)
160. Cohen, E. E. mTOR: the mammalian target of replication. J. Clin. Oncol. 2008, 26(3), 348-349. (Pubitemid 351171681)
161. Rowinsky, E. K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin Oncol., 2004, 16(6), 564-575. (Pubitemid 39482975)
162. Smolewski, P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs, 2006, 17(5), 487-494. (Pubitemid 44309964)
163. Xu, Q.; Simpson, S. E.; Scialla, T. J.; Bagg, A.; Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003, 102(3), 972-980. (Pubitemid 36917792)
164. Recher, C.; Dos Santos, C.; Demur, C.; Payrastre, B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle, 2005, 4(11), 1540-1549.
165. Yee, K. W.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F. J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2006, 12(17), 5165-5173. (Pubitemid 44453345)
166. Perl, A. E.; Carroll, M. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr. Treat. Options Oncol., 2007, 8(4), 265-276.
167. Rizzieri, D. A.; Feldman, E.; Dipersio, J. F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V. M.; Albitar, M.; Bedrosian, C. L.; Giles, F. J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2008, 14(9), 2756-27562.
168. Xu, Q.; Thompson, J. E.; Carroll, M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood, 2005, 106(13), 4261-4268. (Pubitemid 41775935)
169. Xu, R. H.; Pelicano, H.; Zhang, H.; Giles, F. J.; Keating, M. J.; Huang, P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia, 2005, 19(12), 2153-2158. (Pubitemid 41741609)
170. Nishioka, C.; Ikezoe, T.; Yang, J.; Koeffler, H. P.; Yokoyama, A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia, 2008, 22(12), 2159-2168.
171. Janus, A.; Linke, A.; Cebula, B.; Robak, T.; Smolewski, P. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drugs, 2009, 20(8), 693-701.
172. Boehm, A.; Mayerhofer, M.; Herndlhofer, S.; Knoebl, P.; Sillaber, C.; Sperr, W. R.; Jaeger, U.; Valent, P. Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapyrefractory AML. Eur. J. Intern. Med., 2009, 20(8), 775-778.
173. Dunn, C.; Croom, K. F. Everolimus: a review of its use in renal and cardiac transplantation. Drugs, 2006, 66(4), 547-570.
174. Law, M.; Forrester, E.; Chytil, A.; Corsino, P.; Green, G.; Davis, B.; Rowe, T.; Law, B. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res., 2006, 66(2), 1070-1080. (Pubitemid 43165975)
175. Aguirre, D.; Boya, P.; Bellet, D.; Faivre, S.; Troalen, F.; Benard, J.; Saulnier, P.; Hopkins-Donaldson, S.; Zangemeister-Wittke, U.; Kroemer, G.; Raymond, E. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis, 2004, 9(6), 797-805. (Pubitemid 40941208)
176. Shor, B.; Zhang, W. G.; Toral-Barza, L.; Lucas, J.; Abraham, R. T.; Gibbons, J. J.; Yu, K. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res., 2008, 68(8), 2934-2943. (Pubitemid 351556294)
177. Yu, K.; Shi, C.; Toral-Barza, L.; Lucas, J.; Shor, B.; Kim, J. E.; Zhang, W. G.; Mahoney, R.; Gaydos, C.; Tardio, L.; Kim, S. K.; Conant, R.; Curran, K.; Kaplan, J.; Verheijen, J.; Ayral-Kaloustian, S.; Mansour, T. S.; Abraham, R. T.; Zask, A.; Gibbons, J. J. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res., 2010, 70(2), 621-623.
178. Atkins, M. B.; Hidalgo, M.; Stadler, W. M.; Logan, T. F.; Dutcher, J. P.; Hudes, G. R.; Park, Y.; Liou, S. H.; Marshall, B.; Boni, J. P.; Dukart, G.; Sherman, M. L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol., 2004, 22(5), 909-918. (Pubitemid 41103603)
179. Raymond, E.; Alexandre, J.; Faivre, S.; Vera, K.; Materman, E.; Boni, J.; Leister, C.; Korth-Bradley, J.; Hanauske, A.; Armand, J. P. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol., 2004, 22(12), 2336-2347. (Pubitemid 41115390)
180. Mita, M.; Sankhala, K.; Abdel-Karim, I.; Mita, A.; Giles, F. Deforolimus (AP23573) a \novel mTOR inhibitor in clinical development. Expert Opin. Investig. Drugs, 2008, 17(12), 1947-1954.
181. Rahmani, M.; Anderson, A.; Habibi, J. R.; Crabtree, T. R.; Mayo, M.; Harada, H.; Ferreira-Gonzalez, A.; Dent, P.; Grant, S. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood, 2009, 114(20), 4507-4516.
182. Ghobrial, I. M.; Roccaro, A.; Hong, F.; Weller, E.; Rubin, N.; Leduc, R.; Rourke, M.; Chuma, S.; Sacco, A.; Jia, X.; Azab, F.; Azab, A. K.; Rodig, S.; Warren, D.; Harris, B.; Varticovski, L.; Sportelli, P.; Leleu, X.; Anderson, K. C.; Richardson, P. G. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin. Cancer Res., 2010, 16(3), 1033-1041.
183. Park, S.; Chapuis, N.; Tamburini, J.; Bardet, V.; Cornillet-Lefebvre, P.; Willems, L.; Green, A.; Mayeux, P.; Lacombe, C.; Bouscary, D. Role of the PI3K/AKT and mTOR signalling pathways in acute myeloid leukemia. Haematologica., 2010, 95(5), 819-828.
184. Gills, J. J.; Dennis, P. A. Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep., 2009, 11(2), 102-110.
185. Chiarini, F.; Del Sole, M.; Mongiorgi, S.; Gaboardi, G. C.; Cappellini, A.; Mantovani, I.; Follo, M. Y.; McCubrey, J. A.; Martelli, A. M. The novel Akt inhibitor, perifosine, induces caspasedependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 2008, 22(6), 1106-1116. (Pubitemid 351833776)
186. Papa, V.; Tazzari, P. L.; Chiarini, F.; Cappellini, A.; Ricci, F.; Billi, A. M.; Evangelisti, C.; Ottaviani, E.; Martinelli, G.; Testoni, N.; McCubrey, J. A.; Martelli, A. M. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia, 2008, 22(1), 147-160.
187. Tazzari, P. L.; Tabellini, G.; Ricci, F.; Papa, V.; Bortul, R.; Chiarini, F.; Evangelisti, C.; Martinelli, G.; Bontadini, A.; Cocco, L.; McCubrey, J. A.; Martelli, A. M. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res., 2008, 68(22), 9394-9403.
188. Crul, M.; Rosing, H.; de Klerk, G. J.; Dubbelman, R.; Traiser, M.; Reichert, S.; Knebel, N. G.; Schellens, J. H.; Beijnen, J. H.; ten Bokkel Huinink, W. W. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer, 2002, 38(12), 1615-1621. (Pubitemid 34876501)
189. Langen, P.; Maurer, H. R.; Brachwitz, H.; Eckert, K.; Veit, A.; Vollgraf, C. Cytostatic effects of various alkyl phospholipid analogues on different cells in vitro. Anticancer Res., 1992, 12 (6B), 2109-12. (Pubitemid 23105415)
190. Unger, C.; Fleer, E. A.; Kotting, J.; Neumuller, W.; Eibl, H. Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines. Prog. Exp. Tumor Res., 1992, 34, 25-32.
191. Fiegl, M.; Lindner, L. H.; Juergens, M.; Eibl, H.; Hiddemann, W.; Braess, J. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother. Pharmacol., 2008, 62(2), 321-329. (Pubitemid 351692092)
192. Lage, H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets, 2006, 7(7), 813-821.
193. Limtrakul, P.; Chearwae, W.; Shukla, S.; Phisalphong, C.; Ambudkar, S. V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell Biochem., 2007, 296 (1-2), 85-95.
194. van den Heuvel-Eibrink, M. M.; van der Holt, B.; Burnett, A. K.; Knauf, W. U.; Fey, M. F.; Verhoef, G. E.; Vellenga, E.; Ossenkoppele, G. J.; Lowenberg, B.; Sonneveld, P. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann. Hematol., 2007, 86(5), 329-337. (Pubitemid 46477296)
195. Ng, W. F.; Sarangi, F.; Zastawny, R. L.; Veinot-Drebot, L.; Ling, V. Identification of members of the P-glycoprotein multigene family. Mol. Cell Biol., 1989, 9(3), 1224-1232. (Pubitemid 19071691)
196. Hunault, M.; Zhou, D.; Delmer, A.; Ramond, S.; Viguie, F.; Cadiou, M.; Perrot, J. Y.; Levy, V.; Rio, B.; Cymbalista, F.; Zittoun, R.; Marie, J. P. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann. Hematol., 1997, 74(2), 65-71. (Pubitemid 27095478)
197. Archinal-Mattheis, A.; Rzepka, R. W.; Watanabe, T.; Kokubu, N.; Itoh, Y.; Combates, N. J.; Bair, K. W.; Cohen, D. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res., 1995, 7(12), 603-610. (Pubitemid 26107677)
198. Mahadevan, D.; List, A. F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood, 2004, 104(7), 1940-1951. (Pubitemid 39297842)
199. Ross, D, D.; Wooten, P. J.; Sridhara, R.; Ordonez, J. V.; Lee, E. J.; Schiffer, C. A. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood, 1993, 82(4), 1288-1299. (Pubitemid 23254005)
200. List, A. F.; Kopecky, K. J.; Willman, C. L.; Head, D. R.; Persons, D. L.; Slovak, M. L.; Dorr, R.; Karanes, C.; Hynes, H. E.; Doroshow, J. H.; Shurafa, M.; Appelbaum, F. R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood, 2001, 98(12), 3212-3220.
201. Boesch, D.; Gaveriaux, C.; Jachez, B.; Pourtier-Manzanedo, A.; Bollinger, P.; Loor, F. In vivo circumvention of P-glycoproteinmediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 1991, 51(16), 4226-4233.
202. Friche, E.; Jensen, P. B.; Nissen, N. I. Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother. Pharmacol, 1992, 30(3), 235-237.
203. Sonneveld, P.; Burnett, A.; Vossebeld, P.; Ben-Am, M.; Rosenkranz, G.; Pfister, C.; Verhoef, G.; Dekker, A.; Ossenkoppele, G.; Ferrant, C.; Yin, L.; Gratwohl, A.; Kovacsovics, T.; Vellenga, E.; Capdeville, R.; Lowenberg, B. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. Hematol. J., 2000, 1(6), 411-421.
204. Visani, G.; Milligan, D.; Leoni, F.; Chang, J.; Kelsey, S.; Marcus, R.; Powles, R.; Schey, S.; Covelli, A.; Isidori, A.; Litchman, M.; Piccaluga, P. P. Mayer, H.; Malagola, M.; Pfister, C. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia, 2001, 15(5), 764-771. (Pubitemid 32492700)
205. Burnett, A. K.; Milligan, D.; Goldstone, A.; Prentice, A.; McMullin, M. F.; Dennis, M.; Sellwood, E.; Pallis, M.; Russell, N.; Hills, R. K.; Wheatley, K. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br. J. Haematol., 2009, 145(3), 318-332.
206. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of P-glycoprotein- mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res., 1996, 56(18), 4171-4179. (Pubitemid 26305012)
207. Lehne, G.; Morkrid, L.; den Boer, M.; Rugstad, H. E. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int. J. Clin. Pharmacol Ther., 2000, 38(4), 187-195. (Pubitemid 30193614)
208. Callies, S.; de Alwis, D. P.; Wright, J. G.; Sandler, A.; Burgess, M.; Aarons, L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother. Pharmacol., 2003, 51(2), 107-118. (Pubitemid 36259470)
209. Callies, S.; de Alwis, D. P.; Mehta, A.; Burgess, M.; Aarons, L. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979). Cancer Chemother. Pharmacol., 2004, 54(1), 39-48. (Pubitemid 38858364)
210. Gerrard, G.; Payne, E.; Baker, R. J.; Jones, D. T.; Potter, M.; Prentice, H. G.; Ethell, M.; McCullough, H.; Burgess, M.; Mehta, A. B.; Ganeshaguru, K. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica., 2004, 89(7), 782-790. (Pubitemid 38981338)
211. Lancet, J. E.; Baer, M. R.; Duran, G. E.; List, A. F.; Fielding, R.; Marcelletti, J. F.; Multani, P. S.; Sikic, B. I. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk. Res., 2009, 33(8), 1055-1061.
212. van der Velden, V. H.; te Marvelde, J. G.; Hoogeveen, P. G.; Bernstein, I. D.; Houtsmuller, A. B.; Berger, M. S.; van Dongen, J. J. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 2001, 97(10), 3197-3204.
213. Zein, N.; Sinha, A. M.; McGahren, W. J.; Ellestad, G. A. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves doublestranded DNA site specifically. Science, 1988, 240(4856), 1198-1201.
214. Sievers, E. L.; Appelbaum, F. R.; Spielberger, R. T.; Forman, S. J.; Flowers, D.; Smith, F. O.; Shannon-Dorcy, K.; Berger, M. S.; Bernstein, I. D. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 1999, 93(11), 3678-3684. (Pubitemid 29249814)
215. Wadleigh, M.; Richardson, P. G.; Zahrieh, D.; Lee, S. J.; Cutler, C.; Ho, V.; Alyea, E. P.; Antin, J. H.; Stone, R. M.; Soiffer, R. J.; DeAngelo, D. J. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 2003, 102(5), 1578-1582. (Pubitemid 37022544)
216. Cohen, A. D.; Luger, S. M.; Sickles, C.; Mangan, P. A.; Porter, D. L.; Schuster, S. J.; Tsai, D. E.; Nasta, S.; Gewirtz, A. M.; Stadtmauer, E. A. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant, 2002, 30(1), 23-28.
217. Linenberger, M. L.; Hong, T.; Flowers, D.; Sievers, E. L.; Gooley, T. A.; Bennett, J. M.; Berger, M. S.; Leopold, L. H.; Appelbaum, F. R.; Bernstein, I. D. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood, 2001, 98(4), 988-994.
218. Chevallier, P.; Delaunay, J.; Turlure, P.; Pigneux, A.; Hunault, M.; Garand, R.; Guillaume, T.; Avet-Loiseau, H.; Dmytruk, N.; Girault, S.; Milpied, N.; Ifrah, N.; Mohty, M.; Harousseau, J. L. Long-term disease-free survival after gemtuzumab i ntermediate-dose cytarabine, and mitoxantrone in patients with CD33 (+) primary resistant or relapsed acute myeloid leukemia. J. Clin. Oncol., 2008, 26(32), 5192-5197.
219. Litzow, M. R.; Othus, M.; Cripe, L. D.; Gore, S. D.; Lazarus, H. M.; Lee, S. J.; Bennett, J. M.; Paietta, E. M.; Dewald, G. W.; Rowe, J. M.; Tallman, M. S. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br. J. Haematol., 2010, 148(2), 217-225.
220. Candoni, A.; Martinelli, G.; Toffoletti, E.; Chiarvesio, A.; Tiribelli, M.; Malagola, M.; Piccaluga, P. P.; Michelutti, A.; Simeone, E.; Damiani, D.; Russo, D.; Fanin, R.; Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk. Res., 2008, 32(12), 1800-1808.
221. Co, M. S.; Avdalovic, N. M.; Caron, P. C.; Avdalovic, M. V.; Scheinberg, D. A.; Queen, C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol., 1992, 148(4), 1149-1154.
222. Caron, P. C.; Dumont, L.; Scheinberg, D. A. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin. Cancer Res., 1998, 4(6), 1421-1428. (Pubitemid 28265224)
223. Feldman, E.; Kalaycio, M.; Weiner, G.; Frankel, S.; Schulman, P.; Schwartzberg, L.; Jurcic, J.; Velez-Garcia, E.; Seiter, K.; Scheinberg, D.; Levitt, D.; Wedel, N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia, 2003, 17(2), 314-318. (Pubitemid 36266906)
224. Feldman, E. J.; Brandwein, J.; Stone, R.; Kalaycio, M.; Moore, J.; O'Connor, J.; Wedel, N.; Roboz, G. J.; Miller, C.; Chopra, R.; Jurcic, J. C.; Brown, R.; Ehmann, W. C.; Schulman, P.; Frankel, S. R.; De Angelo, D.; Scheinberg, D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol., 2005, 23(18), 4110-4116. (Pubitemid 46211316)
225. Rosenblat, T. L.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Divgi, C. R.; Panageas, K. S.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; Larson, S. M.; Scheinberg, D. A.; Jurcic, J. G. Sequential Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia. Clin. Cancer Res., 2010, Sep. 21 [Epub ahead of print].
226. Presta, L. G.; Chen, H.; O'Connor, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57(20), 4593-4599. (Pubitemid 27441066)
227. Dias, S.; Hattori, K.; Zhu, Z.; Heissig, B.; Choy, M.; Lane, W.; Wu, Y.; Chadburn, A.; Hyjek, E.; Gill, M.; Hicklin, D. J.; Witte, L.; Moore, M. A.; Rafii, S. Autocrine stimulation of \VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest., 2000, 106(4), 511-521. (Pubitemid 30666384)
228. Karp, J. E.; Gojo, I.; Pili, R.; Gocke, C. D.; Greer, J.; Guo, C.; Qian, D.; Morris, L.; Tidwell, M.; Chen, H.; Zwiebel, J. Targeting vascular
229. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 223-241.
230. Van Tendeloo, V. F.; Van de Velde, A.; Van Driessche, A.; Cools, N.; Anguille, S.; Ladell, K.; Gostick, E.; Vermeulen, K.; Pieters, K.; Nijs, G.; Stein, B.; Smits, E. L.; Schroyens, W. A.; Gadisseur, A. P.; Vrelust, I.; Jorens, P. G.; Goossens, H.; de Vries, I. J.; Price, D. A.; Oji, Y.; Oka, Y.; Sugiyama, H.; Berneman, Z. N. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. U S A., 2010, 107, 13824-13829.
231. Mardis, E. R.; Ding, L.; Dooling, D. J.; Larson, D. E.; McLellan, M. D.; Chen, K.; Koboldt, D. C.; Fulton, R. S.; Delehaunty, K. D.; McGrath, S. D.; Fulton, L. A.; Locke, D. P.; Magrini, V. J.; Abbott, R. M.; Vickery, T. L.; Reed, J. S.; Robinson, J. S.; Wylie, T.; Smith, S. M.; Carmichael, L.; Eldred, J. M.; Harris, C. C.; Walker, J.; Peck, J. B.; Du, F.; Dukes, A. F.; Sanderson, G. E.; Brummett, A. M.; Clark, E.; McMichael, J. F.; Meyer, R. J.; Schindler, J. K.; Pohl, C. S.; Wallis, J. W.; Shi, X.; Lin, L.; Schmidt, H.; Tang, Y.; Haipek, C.; Wiechert, M. E.; Ivy, J. V.; Kalicki, J.; Elliott, G.; Ries, R. E.; Payton, J. E.; Westervelt, P.; Tomasson, M. H.; Watson, M. A.; Baty, J.; Heath, S.; Shannon, W. D.; Nagarajan, R.; Link, D. C.; Walter, M. J.; Graubert, T. A.; DiPersio, J. F.; Wilson, R. K.; Ley, T. J.; Recurring mutations found by sequencing an acute yeloid leukemia genome. N. Engl. J. Med., 2009, 361, 1058-1066.